An expanded access record providing Dupilumab in Type 2 Inflammatory Disorders, sponsored by Regeneron Pharmaceuticals. Available. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Regeneron Pharmaceuticals · Expanded access
Provide Compassionate Use or Expanded Access of Dupilumab
Compassionate Use or Expanded Access requests are only being considered in response to Individual Patient or Treatment Investigational New Drug (IND) applications. Availability will depend on location.
1,055 studies on the registry are indexed under Hypersensitivity; 149 are open to participants now.
Browse Hypersensitivity studies →Regeneron Pharmaceuticals is the lead sponsor of 411 studies on the registry; 90 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Eligibility will be determined during the application review process.
To be provided by Regeneron
Also known as: REGN668, DUPIXENT®, SAR231893
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.